Zomedica Corp.: insider trades · United States · SEC (Form 4)

About Zomedica Corp.

Zomedica Corp. is a U.S.-based animal health company focused on veterinary therapeutics and diagnostics. It is currently quoted on the OTCQB under the ticker ZOMDF, and historically has also been associated with the NYSE American market. The company is headquartered in Ann Arbor, Michigan, United States, and was founded in 2015. From an international equity analyst’s perspective, Zomedica is best viewed as a niche animal-health platform targeting veterinarians serving companion animals and horses, with an emphasis on products that can improve both clinical outcomes and practice economics. The company’s business model centers on a portfolio of veterinary devices and diagnostic systems. Its flagship product, PulseVet®, is a shock-wave therapy system used to accelerate healing in musculoskeletal conditions. Zomedica also markets the Assisi® line of therapeutic devices, the TRUFORMA® point-of-care diagnostic platform, the TRUVIEW® digital cytology system, and VetGuardian®, a no-touch monitoring solution. This mix gives the company exposure to multiple revenue drivers: capital equipment, consumables, and broader practice workflow adoption. For veterinarians, the value proposition is straightforward—faster diagnosis, differentiated treatment tools, and solutions designed to improve patient care while supporting clinic efficiency. Competitively, Zomedica operates in a fragmented but highly competitive animal-health market. It is not a scale leader in the global sense; instead, its investment case rests on product innovation, targeted clinical use cases, and the ability to integrate acquired assets into a coherent commercial strategy. Management has highlighted an addressable U.S. market of more than $2 billion across its product set, which signals a meaningful opportunity, but also underscores the level of competition from larger, better-capitalized animal-health companies. As a result, execution quality, sales-force effectiveness, and product adoption trends are central to the stock’s long-term outlook. Geographically, Zomedica’s corporate headquarters are in Ann Arbor, Michigan, and the company manufactures and distributes from facilities in Michigan, Georgia, and Minnesota. It has also discussed Assisi-related distribution operations in New Jersey, which it has been transitioning toward its other facilities. Recent company updates point to ongoing commercial expansion, international growth efforts, and improved operating scale. Zomedica also reported revenue growth in 2025 in its investor materials, while still remaining unprofitable and continuing to invest in R&D, commercialization, and infrastructure. That combination makes the company a classic small-cap growth story: potentially attractive upside if adoption continues, but with clear operational and financial risks. For market context, it is a U.S.-listed name, presently traded on OTCQB under ZOMDF, and previously linked to NYSE American.